| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24024 |
| Drug | Tirzepatide |
| Brand | (Mounjaro®) |
| Indication | For chronic weight management, including weight loss and weight maintenance, in adults with an initial body mass index of: ≥30 kg/m2, or ≥27 kg/m2 to <30 kg/m2 in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). |
| Assessment Process | |
| Rapid review commissioned | 24/06/2024 |
| Rapid review completed | 30/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of tirzepatide for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/08/2024 |
| Pre-submission consultation with Applicant | 15/10/2024 |
| Full submission received from Applicant | 10/04/2025 |
| Preliminary review sent to Applicant | 20/06/2025 |
| NCPE assessment re-commenced | 21/07/2025 |
| Follow-up to preliminary review sent to Applicant | 01/08/2025 |
| NCPE assessment re-commenced | 08/08/2025 |
| Factual accuracy sent to Applicant | 04/11/2025 |
| NCPE assessment re-commenced | 18/11/2025 |
| NCPE assessment completed | 03/12/2025 |
| NCPE assessment outcome | The NCPE recommends that tirzepatide, as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial BMI of: ≥ 30kg/m2, or ≥ 27kg/m2 to < 30kg/m2 in the presence of at least one WRC be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments* |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.